Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDE225 in Acute Leukemia
NCT01826214Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2013
- Primary completion
- May 2015
- Modality
- Allosteric Modulators
- Countries
- 11
01
Overview
Phase 2, randomised, open-label trial of sonidegib in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Novartis. Primary endpoints: Rate of Complete Remission up to 24 months and Complete Remission With Incomplete Blood Count Recovery up to 24 months. Started May 2013; status: completed.
02
Drugs
sonidegib
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT01826214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01826214.